DAA Treatment in Donor HCV-positive to Recipient HCV-negative Liver Transplant
This is a single center study for the donation of HCV-positive livers to HCV negative recipient patients, with preemptive, interventional treatment of Epclusa to prevent HCV transmission upon transplantation.
To view the entire description of the study, click here
The study is to assess treatment with sofosbuvir, velpatasvir and voxilaprevir (Vosevi) in people who were previously treated with a direct-acting antiviral medication but who were not cured. Epclusa plus GS-9857 are the drugs being tested.
Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir (Vosevi) in Subjects With Previous DAA Experience (RESOLVE)
To view the entire clinical trial information, click here